Ravulizumab for the treatment of myasthenia gravis.

Published in: Expert opinion on biological therapy (2023)

Data of the CHAMPION MG trial demonstrate that ravulizumab is effective and safe in the treatment of generalized MG. Having a rapid clinical effect, with long-term clinical response, ravulizumab could represent a selective immunosuppressive drug of choice in the future therapeutic algorithm of MG, where conventional immunosuppressants slowly leave room for newer drugs with a more targeted mechanism of action.

Keyphrases

myasthenia gravis
clinical trial
randomized controlled trial
electronic health record
cancer therapy
phase iii
phase ii
current status
open label